SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 1, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $155K total
Actionable Insight • Neutral

The insider sales are too small to warrant a bearish read-through. Monitor the XOMA acquisition closing (Q3 2026) and upcoming quarterly filings for any change in insider selling patterns. The strong Q1 royalty growth and raised guidance support the current bullish analyst consensus (93% buy).

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$227.44
T+0 close · Apr 30, 2026 · via day close
Latest settled
+30.27%
T+60 · $296.28
Vs SPY
+27.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $227.44entry
  2. T+1 · 7mo ago +0.40%α +0.75% · $228.36
  3. T+5 · 6mo ago −2.65%α −5.00% · $221.41
  4. T+20 · 6mo ago +1.03%α −4.26% · $229.78
  5. T+60 · 4mo ago +30.27%α +27.20% · $296.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligand's strong Q1 earnings (royalty revenue +56% YoY) and the reaffirmation of raised 2026 guidance tied to the pending XOMA acquisition. The sales are small relative to the $4.4B market cap (0.0035%) and likely reflect routine portfolio rebalancing or tax planning, not a bearish signal on fundamentals.

Key Financial Metrics

Direction
selling
Total Value
$155.0K
Insiders
2

Key Facts

  • Two insiders sold a total of 680 shares for $155K on May 1, 2026.
  • Sales represent ~0.0035% of Ligand's $4.4B market cap, trivial in size.
  • Director Kozarich also exercised and sold shares on May 12-13, 2026, in a separate cluster ($455K total).
  • Q1 2026 earnings showed royalty revenue up 56% YoY to $43M; adjusted EPS of $1.63 beat prior year's $1.33.
  • Ligand reaffirmed raised 2026 guidance: adjusted EPS $8.50-$9.50, royalty revenue $225M-$250M.
  • Pending XOMA acquisition ($39/share cash + CVR) expected to close in Q3 2026.

Financial Impact

Insider sales of $155K are immaterial relative to $4.4B market cap.

insider_sales_volume

Risk Factors

  • Pending XOMA acquisition may face stockholder approval or regulatory delays.
  • Captisol sales declined 36% YoY in Q1 2026 due to customer order timing.
  • Non-cash loss on Pelthos investment ($49.2M) drove GAAP net loss of $13.3M.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LGND-1778807348557

US Market Status

Market Closed · Opens Wed (10h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026